期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

CYP3A4* 1G基因多态性及功能的初步探讨 被引量：1

Preliminary study of the function of CYP3A4* 1G polymorphism
下载PDF
导出
摘要 目的:采用双荧光素酶报告基因系统分析CYP3A4*1G多态性对CYP3A4基因转录活性的影响。方法:构建含CYP3A4*1G突变位点的荧光素酶基因表达载体,用Lipofectamine 2000转染HepG2细胞,化学发光法检测荧光素酶活性。结果:应用双荧光素酶报告基因系统检测显示,pGL3-promoter-A质粒转染后荧光素酶活性显著高于pGL3-promoter-G(P=0.022<0.05)。结论:CYP3A4*1G能够增强荧光素酶基因的表达,可能增强CYP3A4基因的转录活性。 Objective： To analyze the effects of CYP3A4 ＊ 1G polymorphism on the transcriptional activity of the CYP3A4 gene by the dual luciferase reporter assay system. Methods： The luciferase gene plasmids containing the CYP3A4 ＊ 1G mutated sites was constructed by genetic engineering. The human hepatoma cell line, HepG2, was used for transfection with the plasmid constructs by li- pofectamine 2000. Results： The results of the dual luciferase reporter assay system indicated that the IVS10 ＋ 12A construct showed higher luciferase activity than the IVS10 ＋ 12G construct （P =0. 022）. Conclusion： The CYP3A4 ＊ 1G is able to enhance the expression of the luciferase gene, which implies that it may enhance the transcriptional activity of CYP3A4 gene.
作者 贺宝霞 赵秀莉 石磊 赵树进
机构地区 郑州大学附属肿瘤医院药学部 广州军区广州总医院药学部
出处 《河南医学研究》 CAS 2014年第7期4-7,共4页 Henan Medical Research
基金 国家自然科学基金项目(81302796) 河南省医学科技攻关计划项目(201203148)
关键词 细胞色素P4503A4 基因多态性 双荧光素酶报告基因系统 CYP3A4 genetic polymorphism dual luciferase reporter assay system
分类号 R394-33 [医药卫生—医学遗传学]
  • 相关文献

参考文献10

  • 1Du J, Yu L, Wang L, et al. Differences in CYP3A41G genotype dis- tribution and haplotypes of CYP3A4, CYP3A5 and CYP3A7 in 3 Chi- nese populations[J]. Clin Chim Acta, 2007, 383(1-2) : 172-174.
  • 2SambrookJ RussellD 黄培堂译.分子克隆实验指南[M]第3版[M].北京:科学出版社,2002.409.
  • 3Fukushima-Uesaka H, Saito Y, Watanabe H, et al. Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japa- nese population[ J]. Hum Mutat, 2004, 23 ( 1 ) : 100.
  • 4Hu Y F, Tu J H, Tan Z R, et al. Association of CYP3A4 * 18B pol- ymorphisms with the pharmacokinetics of cyclosporine in healthy sub- jects[ J]. Xenobiotica, 2007, 37 (3): 315-327.
  • 5Qiu X Y, Jiao Z, Zhang M, et al. Association of MDR1, CYP3A4 * 18B, and CYP3A5 * 3 polymorphisms with cyclosporine pharmacoki-netics in Chinese renal transplant recipients[ J]. Eur J Clin Pharma- col, 2008, 64(11): 1069-1084.
  • 6Du J, Zhang A, Wang L, et al. Relationship between response to ris- peridone, plasma concentrations of risperidone and CYP3A4 polymor- phisms in schizophrenia patients [ J ]. J Psychopharmacol, 2010, 24 (7) : 1115-1120.
  • 7Angiolillo D J, Fernandez-Ortiz A, Bernardo E, et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel [ J ]. Arterio- seler Thromb Vase Biol, 2006, 26(8) : 1895-2900.
  • 8Zhang W, Chang Y Z, Kan Q C, et al. CYP3A4 * 1G genetic poly- morphism influences CYP3A activity and response to fentanyl in Chi- nese gynecologic patients[J]. Eur J Clin Pharmaeol, 2010, 66( 1 ) : 61-66.
  • 9Yuan R, Zhang X, Deng Q, et al. Impact of CYP3A4 * IG polymor- phism on metabolism of fentanyl in Chinesepatients undergoing lower abdominal surgery [ J ]. Clin Cbim Acta, 2011, 412 ( 9-10 ) : 755-760.
  • 10Gao Y, Zhang LR, Fu Q. CYP3A4 * 1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin [ J]. Eur J Clin Pharmacol, 2008, 64(9) : 877-882:

共引文献27

同被引文献16

  • 1舒芬太尼多中心研讨会纪要[J].临床麻醉学杂志,2004,20(11):668-668. 被引量：48
  • 2Zhang W, Chang YZ, Kan QC, et al. CYP3A4 * 1G genetic polymorphism influences CYP3A activity and response to fent- anyl in Chinese gynecologic patients[J]. Eur J Clin Pharma- col, 2010, 66(1): 61-66.
  • 3Yuan R, Zhang X, Deng Q, et al. Impact of CYP3A4 * 1G polymorphism on metabolism of fentanyl in Chinese patients undergoing lower abdominal surgery I-J]. Clin China Acta, 2011, 412(9/10): 755-760.
  • 4Liao Q, Chen DJ, Zhang F, et al. Effect of CYP3A4 * 18B polymorphisms and interactions with OPRM1 A118G on post- operative fentanyl requirements in patients undergoing radical gastrectomy[J]. Mol Med Rep, 2013, 7(3).- 901-908.
  • 5Fukushima-Uesaka H, Saito Y, Watanabe H, etal. Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Jap- anese population[J]. Hum Mutat, 2004, 23(1) : 100.
  • 6Tateishi T, Krivoruk Y, Ueng YF, et al. Identifieation of hu- man liver eytoehrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation [J]. Anesth Analg, 1996, 82(1): 167-172.
  • 7Guitton J, Buronfosse T, D6sage M, et al. Possible involve- ment of multiple eytoehrome P450S in fentanyl and sufentanil metabolism as opposed to alfentanil[J]. Bioehem Pharmaeol, 1997, 53(11): 1613-1619.
  • 8Eriksen J, Berthelsen P, Ahn NC, et al. Early response incentral hemodynamics to high doses of sufentanil or morphine in dogs[J]. Acta Anaesthesiol Scand, 1981, 25(1): 33-38.
  • 9Edwards ND, Alford AM, Dobson PM, et al. Myocardial is chemia during tracheal intubation and extubation[J]. Br J An- aesth, 1994, 73(4): 537-539.
  • 10Tan PC, Hassan SK, Mohamad NA, et al. Cytochrome P450 3A4 genetic polymorphisms and post-operative fentanyl re- quirements[J]. J Clin Pharm Ther, 2012, 37(1) : 100-104.

引证文献1

二级引证文献4

河南医学研究
2014年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部